Molecular Biology and Genetics / Moleküler Biyoloji ve Genetik

Permanent URI for this collectionhttps://hdl.handle.net/11147/9

Browse

Filters

2022 - 20232

Settings

Scopus Q: search.filters.scopusQuartile.Q1Subject: search.filters.subject.Tumor microenvironment

Search Results

Now showing 1 - 2 of 2
  • Article
    Citation - WoS: 11
    Citation - Scopus: 13
    Fli1 and Fra1 Transcription Factors Drive the Transcriptional Regulatory Networks Characterizing Muscle Invasive Bladder Cancer
    (Nature Research, 2023) Güneri Sözeri, Perihan Yağmur; Özden Yılmaz, Gülden; Kısım, Aslı; Çakıroğlu, Ece; Eray, Aleyna; Uzuner, Hamdiye; Karakülah, Gökhan; Pesen Okvur, Devrim; Şentürk, Şerif; Erkek Özhan, Serap
    is and progression of this disease. In this study, we defined the active regulatory landscape of MIBC and NMIBC cell lines using H3K27ac ChIP-seq and used an integrative approach to combine our findings with existing data. Our analysis revealed FRA1 and FLI1 as two critical transcription factors differentially regulating MIBC regulatory landscape. We show that FRA1 and FLI1 regulate the genes involved in epithelial cell migration and cell junction organization. Knock-down of FRA1 and FLI1 in MIBC revealed the downregulation of several EMT-related genes such as MAP4K4 and FLOT1. Further, ChIP-SICAP performed for FRA1 and FLI1 enabled us to infer chromatin binding partners of these transcription factors and link this information with their target genes. Finally, we show that knock-down of FRA1 and FLI1 result in significant reduction of invasion capacity of MIBC cells towards muscle microenvironment using IC-CHIP assays. Our results collectively highlight the role of these transcription factors in selection and design of targeted options for treatment of MIBC.
  • Article
    Citation - WoS: 9
    Citation - Scopus: 11
    Mir-Aculous New Avenues for Cancer Immunotherapy
    (Frontiers Media S.A., 2022) Tang, William W.; Bauer, Kaylyn M.; Barba, Cindy; Ekiz, Hüseyin Atakan; O’Connell, Ryan M.
    The rising toll of cancer globally necessitates ingenuity in early detection and therapy. In the last decade, the utilization of immune signatures and immune-based therapies has made significant progress in the clinic; however, clinical standards leave many current and future patients without options. Non-coding RNAs, specifically microRNAs, have been explored in pre-clinical contexts with tremendous success. MicroRNAs play indispensable roles in programming the interactions between immune and cancer cells, many of which are current or potential immunotherapy targets. MicroRNAs mechanistically control a network of target genes that can alter immune and cancer cell biology. These insights provide us with opportunities and tools that may complement and improve immunotherapies. In this review, we discuss immune and cancer cell–derived miRNAs that regulate cancer immunity and examine miRNAs as an integral part of cancer diagnosis, classification, and therapy.